CAP

AIxMed Welcomes Barbara Crothers, D.O., as Chief Scientist and Appoints Two Scientific Advisors

Retrieved on: 
Monday, June 5, 2023

SANTA CLARA, Calif., June 5, 2023 /PRNewswire/ -- AIxMed, an early-stage smart Cytology company at the intersection of artificial intelligence (AI) and medicine, announced the appointment of Cytopathology industry heavyweight Barbara Crothers, D.O., as Chief Scientist. In this new executive leadership role, Dr. Crothers will drive AIxMed's strategic scientific and clinical initiatives. This includes leading U.S.-based pilot and validation studies of the AIxMed digital Cytology platform.

Key Points: 
  • In this new executive leadership role, Dr. Crothers will drive AIxMed's strategic scientific and clinical initiatives.
  • This includes leading U.S.-based pilot and validation studies of the AIxMed digital Cytology platform.
  • Dr. Crothers is joining in our AI-driven mission to improve workflows and patient care in the battle against cancer.
  • At AIxMed, she will apply these strong credentials towards positioning the Company's technology at the leading edge of the Pathology digital revolution.

Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design

Retrieved on: 
Wednesday, May 31, 2023

FDA agreed to the proposed expansion of the confirmatory Phase 3 study in S. aureus ventilator associated pneumonia (VAP) patients to include ventilated hospital acquired pneumonia (HAP) and ventilated community acquired pneumonia (CAP) patients.

Key Points: 
  • FDA agreed to the proposed expansion of the confirmatory Phase 3 study in S. aureus ventilator associated pneumonia (VAP) patients to include ventilated hospital acquired pneumonia (HAP) and ventilated community acquired pneumonia (CAP) patients.
  • The clinical efficacy endpoint will be the same endpoint of Clinical Cure of pneumonia on Day 21 used in the previous Phase 3 superiority trial AR-301-002.
  • The confirmatory AR-301-003 Phase 3 superiority study will be powered for efficacy in both the primary efficacy endpoint in adults ≥65 years of age, and for the key secondary efficacy endpoint in all study subjects (≥65 and “We are particularly gratified to reach concurrence with the FDA on the overall study design, endpoints, and patient populations,” said Aridis CEO Vu Truong.
  • “This provides a clear clinical and regulatory pathway to bring AR-301 to patients with high unmet medical needs and enhances the opportunity for potential pharma partners.”

Rimini Street Announces the 2023 RMNI LOVE™ $50,000 Grant Program Winners

Retrieved on: 
Wednesday, May 31, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230531005329/en/
    Rimini Street announces the recipients of its 2023 $50,000 RMNI LOVE™ Grant Program.
  • (Photo: Business Wire)
    The final winners of the program were 10s and 20s Pregnancy SOS, Empowerment Kanagawa, Family House, Food Bank Shibuya and Shine On!
  • The rigorous process of selecting the top five charities to receive the grant administered by the Rimini Street Foundation – the privately funded charitable program of Rimini Street, Inc. and its global subsidiaries – involved a three-tiered qualification, elimination and voting method.
  • The $10,000 grant will go towards expanding their counseling program, which will help identify chronic issues and appropriate long-term solutions.

IntelePeer Appoints Sergey Galchenko to Chief Technology Officer

Retrieved on: 
Wednesday, May 31, 2023

IntelePeer , a leading Communications Automation Platform provider, announces the appointment of Sergey Galchenko to Chief Technology Officer.

Key Points: 
  • IntelePeer , a leading Communications Automation Platform provider, announces the appointment of Sergey Galchenko to Chief Technology Officer.
  • At INTURN, he served as Chief Technology Officer and VP of Engineering, overseeing the implementation of new technology strategies and solutions.
  • He was also Chief Technology Officer for Star2Star, where his responsibilities involved strategic technical leadership, and managing its applications portfolio.
  • Likewise, Galchenko held the role of Technology Director at Jo-Ann Stores and was previously Chief Technology Officer at BroadVox.

True Reconciliation Lies in the Hands of Senators

Retrieved on: 
Tuesday, May 23, 2023

The oversight body is a "Call to Action" from the Truth and Reconciliation Commission's 2015 report.

Key Points: 
  • The oversight body is a "Call to Action" from the Truth and Reconciliation Commission's 2015 report.
  • "Senators now have the opportunity to make reconciliation inclusive for all Indigenous Peoples," says CAP National Chief Elmer St. Pierre.
  • CAP is encouraging all Senators to use practical sense and ensure CAP has a permanent seat on the board of directors.
  • After centuries of colonialism, racism and exclusion, CAP is calling on Senators to change direction and make reconciliation inclusive for all Indigenous Peoples.

Government Must Not Use Reconciliation As A Tool For Assimilation

Retrieved on: 
Wednesday, May 17, 2023

The oversight body is a "Call to Action" from the Truth and Reconciliation Commission's 2015 report.

Key Points: 
  • The oversight body is a "Call to Action" from the Truth and Reconciliation Commission's 2015 report.
  • It is vital that urban Indigenous voices and CAP have a seat at the table, and therefore Senators must make an amendment allowing us to take part.
  • "There are five National Indigenous Organizations, but for some reason the Liberal Government is playing partisan politics excluding CAP and the voices of urban Indigenous peoples."
  • "The government is attempting to divide and conquer, choosing who they consider Indigenous," says CAP National Vice-Chief Kim Beaudin.

Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh

Retrieved on: 
Monday, May 22, 2023

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has opened a new state-of-the-art laboratory facility in Pittsburgh.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has opened a new state-of-the-art laboratory facility in Pittsburgh.
  • “Castle is proud to be a member of the Pittsburgh community and grow our footprint in this great city,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.
  • Castle expects to have the capacity and ability to process each of its proprietary tests out of the new laboratory.
  • The new laboratory in Pittsburgh brings Castle’s total laboratory operations space to more than 52,000 square feet combined.

inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology

Retrieved on: 
Thursday, May 18, 2023

The inFoods® IBS diagnostic test has now been validated for use with finger stick (capillary) patient whole blood samples simplifying sample collection and facilitating wider access to the test.

Key Points: 
  • The inFoods® IBS diagnostic test has now been validated for use with finger stick (capillary) patient whole blood samples simplifying sample collection and facilitating wider access to the test.
  • This workflow enhancement greatly simplifies the process for healthcare providers to order the inFoods IBS test and is much easier for patients.
  • The InFoods IBS test will continue to be available using blood collected from a patient’s arm (venipuncture) by a trained phlebotomist.
  • "By enabling the use of finger stick whole blood samples, we're making our personalized IBS therapy more convenient and easier than ever.

Highlights - Presentation of ECA Special Report on conflict of interest in CAP and cohesion policy - Committee on Budgetary Control

Retrieved on: 
Wednesday, May 17, 2023

Presentation of ECA Special Report on conflict of interest in CAP and cohesion policy

Key Points: 

Presentation of ECA Special Report on conflict of interest in CAP and cohesion policy
17-05-2023 - 16:17
On 24 May 2023, Pietro Russo, Member of the European Court of Auditors, will present special report 06/2023 "Conflict of interest in EU cohesion and agricultural spending" to CONT Committees, with invited Members from REGI and AGRI Committees.

2023 CAP Consumer Surveys Continue to Show the Benefits of Effective Site Blocking

Retrieved on: 
Monday, May 15, 2023

Notably, rights holders face challenges in procuring effective and efficient site blocking in all three of these countries.

Key Points: 
  • Notably, rights holders face challenges in procuring effective and efficient site blocking in all three of these countries.
  • These consumer surveys acknowledge site blocking as an effective tool to mitigate piracy harm.
  • However there remains issues with the time and cost involved with obtaining site blocking orders in Singapore.
  • The surveys will continue to be repeated across the same countries annually, and in doing so, will continue to provide longitudinal analysis of consumer behavioral trends towards piracy and enforcement measures around the region.